Pre-clinical studies with trastuzumab-, lapatinib-, and afatinib-resistant GC cell lines revealed increased levels of mesenchymal markers, such as vimentin and testican-1, with a concurrent decrease in E-cadherin to promote an aggressive EMT phenotype [141,142,143]. Here, VIM is linked to gastric cancer.